Eurofins Expands Kidney Transplant Diagnostics Offering Through Viracor TRAC™


Viracor announces a donor derived cell-free DNA (dd-cfDNA) assay, Viracor TRAC™, to complement its suite of testing that supports successful outcomes for patients with kidney transplants. Viracor TRAC™ Kidney is now available to order.

Viracor Eurofins Expands Its Clinical Diagnostic Footprint to Oncology


Dr. Karina Eterovic joins Viracor as the Director of Research & Development for Oncology Diagnostics for Eurofins U.S. Clinical Diagnostics group

MolDX Sets TruGraf Reimbursement Level


Transplant Genomics, Inc. receives notice that the Molecular Diagnostics Services (MolDX) Program developed by Palmetto GBA has set TruGraf reimbursement.

Transplant Genomics, Inc. Confirms TruGraf Will Receive Medicare Coverage Effective November 25, 2019


Transplant Genomics and Viracor's innovative TruGraf ® Blood Gene Expression Test qualifies for Medicare coverage effective November 25, 2019. 

Eurofins Viracor, Inc. Responds to Patent Infringement Lawsuit By CareDx


Eurofins Viracor, Inc. (“Viracor”) became aware today that CareDx has filed suit in the United States District Court for District of Delaware, alleging infringement of U.S. Patent No. 8,703,652 by three of Viracor’s tests:  Viracor TRAC™ Kidney dd-cfDNA, Viracor TRAC™ Heart dd-cfDNA and Viracor TRAC™ Lung dd-cfDNA.

Viracor Eurofins Collaborates with Northwestern University Comprehensive Transplant Center on Specialized Kidney Transplant Diagnostic


Viracor Eurofins announces research collaboration with the Northwestern University Comprehensive Transplant Center, a leader in solid organ transplantation medicine in North America through high impact research and its clinical training programs. This research collaboration will further verify the novel test obtained through Eurofins’ recent acquisition of Transplant Genomics Inc. (“TGI”), and its blood gene expression test, TruGraf®.

Eurofins Expands its Transplantation Testing Footprint with the Acquisition of Transplant Genomics Inc.


Eurofins Scientific (EUFI.PA), announces that it has successfully closed the acquisition of Transplant Genomics Inc. (“TGI”), a molecular diagnostics company committed to improving organ transplant outcomes with non-invasive serial monitoring guided by genomics. TGI’s innovative non-invasive tests for the management of patients with silent inflammation and rejection following kidney transplants will strengthen and complement Eurofins’ industry leading global Transplant Diagnostics offerings.

Viracor Eurofins Launches Baloxavir marboxil (XOFLUZA™) Influenza A Antiviral Resistance PCR for 2019 Flu Season


Baloxavir Resistance Testing was developed for the detection of I38T/M/F mutations in H3N2 and 2009 H1N1 strains of Influenza A (flu A) to aid in the evaluation of resistance to the recent FDA approved drug. 

16S Next Generation Sequencing Bacterial Meningitis test from Viracor Eurofins provides actionable results to improve patient outcomes


Healthcare professionals can detect and identify the most common bacterial pathogens
associated with meningitis, with results in 3 days

Viracor Eurofins offers first commercially available letermovir genotypic sequencing test to help healthcare professionals manage CMV


Innovative Options in CMV Testing Plus Industry-Leading Turnaround Time Helps Reduce the Risk for CMV Morbidity and Mortality

Viracor Eurofins Announces Medical Advisory Board


Industry-leading infectious disease and transplant physicians help Viracor ideate and innovate to serve unmet testing needs, improving patient care and outcomes

Viracor Eurofins' Algorithms Predict Risk of aGVHD and Non-relapse Mortality in Allogeneic HCT Patients


New algorithms with clinically validated cutoffs aid in treatment decisions and modifications prior to or early in the disease process, to improve patient outcomes 

Eurofins Scientific Donates €1 Million to Mark its 30-Year Anniversary


Eurofins Scientific (EUFI.PA) marks its 30th anniversary by donating €1 million to 40 charities selected by its global workforce.

Viracor-IBT Laboratories, Inc.’s Zika Virus RT-PCR Test Receives Emergency Use Authorization From the FDA


Test Provides U.S. Physicians and Patients Same Day Results and the Option to Test Urine Alongside Blood

The National Kidney Registry Partners with Viracor-IBT Laboratories to Accelerate Living Donor Transplantation


The National Kidney Registry (NKR) and Viracor-IBT Laboratories announced today a partnership to streamline pre-transplant serology testing for kidney donors.

Viracor-IBT Partners with USA Today Transplant Coverage


Viracor-IBT is excited to partner with USA Today's Transplants: The Gift of Life, an annual supplement bringing attention to transplantation and the organ donation industries united work to raise awareness about gifting one's organs in order to help save the lives of others.

Published scientific study proves efficacy of ImmuKnow® test, improving patient survival rate


The study demonstrated that the ImmuKnow assay provided additional data which helped optimize immunosuppression, and ultimately improve patient survival rate3.

Eurofins signs agreement to acquire Viracor-IBT Laboratories, Inc.


Eurofins Scientific (EUFI.PA), the global leader in bio-analytical testing, and one of the world leaders in genomic services, has signed a definitive agreement to acquire ViraCor-IBT Laboratories, Inc. (VIBT) from majority owner Ampersand Capital and other shareholders for approximately $255m, subject to post-closing adjustments.

Viracor-IBT Laboratories' Acquisition of the National Institute of Transplantation Enhances Testing Services for Transplant Patients.


Viracor-IBT Laboratories, Inc. announced today it has closed on its previously announced transaction to purchase assets associated with the laboratory operations of the National Institute of Transplantation (NIT), a non-profit organization committed to advancing the science and practice of transplantation. NIT made the decision to transfer its laboratory operations to Viracor-IBT to perpetuate the mission of its foundation, build on the legacy of its laboratory operations, and to provide testing services to more transplant patients across the U.S.

Viracor-IBT Laboratories Acquires Assets of the National Institute of Transplantation


Viracor-IBT Laboratories, Inc. announced today it has signed a definitive agreement to purchase all assets associated with the laboratory operations of the National Institute of Transplantation (NIT), a non-profit organization committed to advancing the science and practice of transplantation.

Viracor-IBT Laboratories Acquires Assets of Cylex™


Viracor-IBT Laboratories, Inc. announced today that it has signed a definitive agreement to purchase the assets of CylexTM, Inc., a global life sciences company focused on the development, manufacturing and commercialization of in vitro diagnostic products intended to illuminate immunity in the area of transplant medicine. 

Viracor-IBT Laboratories Launches the First Assay to Identify a New Type of Delayed, IgE-based Allergic Reaction to Certain Meats


New Alpha-Gal IgE assay is the first to specifically detect antibodies associated with a delayed-onset allergic reaction to beef, pork, and lamb, the development of which has been linked to tick bites.

Viracor-IBT Laboratories Expands Fungal Testing Services with Launch of Aspergillus PCR Panel


New testing service is the first to detect and measure deadly Invasive Pulmonary Aspergillosis

Viracor-IBT Laboratories to Present at the American College of Allergy, Asthma and Immunology’s Annual Meeting


Scientists from Viracor-IBT Laboratories have been selected to provide four oral presentations and one poster presentation at this year’s American College of Allergy, Asthma and Immunology’s Annual Scientific Meeting in Miami, Florida.

Viracor-IBT Laboratories Launches Comprehensive Influenza and Respiratory Virus Testing Service


New suite of tests identifies 2009 Influenza A H1N1 ("swine flu"), additional influenza subtypes and other common respiratory viruses, assisting physicians in improving patient care and ensuring appropriate antiviral use.

ViraCor Laboratories and IBT Laboratories Merging to Create Unique Specialty Diagnostics Company


Combined company draws on latest scientific research to provide the most accurate, reliable and comprehensive immunology and infectious disease tests available.

ViraCor Laboratories Launches Ultrasensitive JC Virus Test


New test will assist in the earlier diagnosis of Progressive Multifocal Leukoencephalopathy, a serious brain infection exclusively caused by JCV.

ViraCor Laboratories Launches Fastest Available Cytomegalovirus Antiviral Resistance Test


New Service Provides Comprehensive Detection of Antiviral Resistant Virus Strains in Just Three Days, Helping Physicians Treat Patients Quickly, Improve Patient Outcomes and Reduce Healthcare Costs.

ViraCor Laboratories Helps Hospitals Effectively Navigate Impending Flu Season


Unique clinical reference and research lab offers complex respiratory virus testing that improves patient care by allowing doctors to identify an infection quickly and accurately.

ViraCor Laboratories Launches Comprehensive Testing for Fungal Infections


Service begins with the introduction of two tests Platelia Aspergillus EIA and Fungitell β-D Glucan

ViraCor’s Founder and CEO Flip Short Named 2008 Ernst & Young Entrepreneur Of The Year® in the Central Midwest Region


Award Recognizes Entrepreneurial Excellence in Life Sciences Category

ViraCor Laboratories Launches New Enterovirus Test


National Clinical Reference Laboratory Provides Results in Less Than 24 Hours, Leading to Faster Diagnosis of Virus that Infects Millions of Americans Each Year

IBT Laboratories to Launch New Pneumococcal Antibody Avidity Test at AAAAI Meeting


Test builds on company's suite of tests to evaluate immune function

ViraCor Laboratories Is First National Reference Laboratory To Offer Novel Respiratory Viral Testing


Newly-Cleared Respiratory Viral Panel Enables Clinicians to Improve Patient Care through Fast and Accurate Laboratory Diagnosis